Analysts have been eager to weigh in on the Healthcare sector with new ratings on Roche Holding AG (RHHVF) and Protagonist Therapeutics (PTGX).
Roche Holding AG (RHHVF)
In a report issued on June 11, Luisa Hector from Berenberg Bank maintained a Hold rating on Roche Holding AG, with a price target of CHF340.00. The company’s shares closed last Friday at $380.00, close to its 52-week high of $388.50.
According to TipRanks.com, Hector is ranked #3941 out of 7551 analysts.
Currently, the analyst consensus on Roche Holding AG is a Hold with an average price target of $390.59, a 2.8% upside from current levels. In a report issued on June 2, Societe Generale also downgraded the stock to Hold with a CHF340.00 price target.
See today’s analyst top recommended stocks >>
Protagonist Therapeutics (PTGX)
Northland Securities analyst Tim Chiang maintained a Buy rating on Protagonist Therapeutics on June 11 and set a price target of $47.00. The company’s shares closed last Friday at $39.64, close to its 52-week high of $40.46.
According to TipRanks.com, Chiang is a 2-star analyst with an average return of 0.5% and a 51.1% success rate. Chiang covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Verrica Pharmaceuticals, and Pacira Pharmaceuticals.
Currently, the analyst consensus on Protagonist Therapeutics is a Strong Buy with an average price target of $48.67, which is a 44.3% upside from current levels. In a report issued on June 3, JMP Securities also reiterated a Buy rating on the stock with a $48.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
